The aim of the present report is to assess the added benefit of the drug dasabuvir in comparison with dual therapy of peginterferon and ribavirin (PEG + RBV) or triple therapy of telaprevir, peginterferon and ribavirin (TVR + PEG + RBV) as appropriate comparator therapy (ACT) in patients with chronic hepatitis C (CHC) genotype 1.
http://ift.tt/2seyu5L
Πέμπτη 15 Ιουνίου 2017
Dasabuvir -- Benefit Assessment According to §35a Social Code Book V [Internet].
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Summary Insulinomas are rare neuroendocrine tumours that classically present with fasting hypoglycaemia. This case report discusses an un...
-
The online platform for Taylor & Francis Online content New for Canadian Journal of Remote Sen...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου